Skip to content

Wound Infections Following Implant Removal

Antibiotic Prophylaxis to Prevent Wound Infections Following Implant Removal

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02225821
Acronym
WIFI
Enrollment
500
Registered
2014-08-26
Start date
2014-11-30
Completion date
2016-11-30
Last updated
2016-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Wound Infection

Keywords

Implant Removal, Antibiotic Prophylaxis, Postoperative wound infection, Orthopedics

Brief summary

In the Netherlands about 18,000 surgical procedures with implant removal are annually performed after fracture healing, of which 30-80% concern the foot, ankle and lower leg region. For clean surgical procedures, the rate of postoperative wound infections (POWIs) should be less than 5%. However, rates of 10-12% following implant removal, specifically after foot, ankle and lower leg fractures are reported. Currently, surgeons decide individually if antibiotics prophylaxis is given, since no guideline exists. This leads to undesirable practice variation. Therefore, the investigators propose a double-blind randomized controlled trial (RCT) in patients scheduled for implant removal following a foot, ankle or lower leg fracture, to assess the (cost-)effectiveness of a single gift of antibiotic prophylaxis. Primary outcome is a POWI within 30 days after implant removal. Secondary outcomes are quality of life, functional outcome at 30 days and 6 months after implant removal and costs. With 2 x 250 patients a decrease in POWI from 10% to 3.3% (expected rate in clean-contaminated elective orthopedic trauma procedures) can be detected (Power=80%, 2-sided alpha=5%, including 15% lost to follow up). If the assumption of the investigators, that prophylactic antibiotics prior to implant removal reduces the infectious complication rate, is confirmed by this RCT, this will offer a strong argument to adopt a single gift of antibiotic prophylaxis as standard practice of care. This will reduce the incidence of POWIs and consequently will lead to less physical and social disabilities and health care use. In addition, it will decrease the rate of use of empiric broad-spectrum antibiotics (and antibiotic resistance) prescribed upon suspicion or diagnosis of a POWI. A preliminary, conservative estimation suggests yearly cost savings in the Netherlands of €3.5 million per year.

Detailed description

See study protocol

Interventions

DRUGCephalozin

1000 mg Cephalozin

OTHERSodium chloride

10 cc of NaCl 0.9%

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
AO Research Fund
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients ≥18 years and ≤75 years of all ethnic backgrounds * Implant removal following foot, ankle and/or lower leg surgery

Exclusion criteria

* Removing and re-implanting osteosynthesis material in the same session * Active wound infection or (plate) fistula * Antibiotic treatment at time of elective implant removal for a concomitant disease or infection * A medical history of an allergic reaction to a cephalosporin, penicillin, or any other β-lactam antibiotic. * Insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate. * Kidney disease (eGFR \<60 ml/min/1.73m\^2). * Treatment with probenecide, anticoagulants (see SPC) * Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
Postoperative wound infection (POWI)30 daysThe primary outcome variable is a POWI within 30 days after implant removal as defined by the criteria applied by the Centers for Disease and Control.

Secondary

MeasureTime frameDescription
Health-related quality of lifebaseline, one month, 6 monthsHealth-related quality of life (as measured by the EQ-5D questionnaire)
Functional outcomebaseline, 1 month, 6 monthsFunctional outcome following implant removal as assessed with the Lower Extremity Functional Scale (LEFS). The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress and outcome, as well as to set functional goals. The LEFS can be used to evaluate the functional impairment of a patient with a disorder of one or both lower extremities. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention
Patient satisfaction1 month, 6 monthsPatient satisfaction following implant removal as measured by a ten-point Visual Analog Scale
Health care resources utilizationbaseline, 1 month, 6 monthsHealth care resources utilization at baseline, 1 month and 6 months after implant removal (including amongst others, number of visits to the general practitioner and use of home care organizations) as measured by way of a combination of the Dutch iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) (adapted to the study setting).

Other

MeasureTime frameDescription
CostsCosts per quality adjusted life yearCosts (economic evaluation including budget impact analysis): the economic evaluation of antibiotic prophylaxis in patients scheduled for implant removal (following a foot, ankle or lower leg fracture) against no prophylaxis as its best alternative will be performed as a cost-effectiveness (CEA) as well as a cost-utility (CUA) analysis.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026